ArticleBMJ open2022
Prevalence and risk factors of metabolic-associated fatty liver disease during 2014-2018 from three cities of Liaoning Province: an epidemiological survey.
Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Creatinine-to-body weight ratio as an independent predictor of hepatic steatosis severity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.BMC gastroenterology · 2026Article
- The development and evaluation of nine non-conventional lipid parameters for metabolic dysfunction-associated fatty liver disease in Chinese medical health examination adults: a single-center retrospective study.Frontiers in nutrition · 2026Article
- A 100 mg/kg Dose of Naringenin as an Anti-Obesity Agent for Eight Weeks Exerts No Apparent Hepatotoxic or Nephrotoxic Effects in Wistar Rats.Foods (Basel, Switzerland) · 2025Article
- Prevalence, demographic characteristics and clinical profile of metabolic dysfunction-associated fatty liver disease among adult patients attending tertiary hospitals in Dodoma, Tanzania. a cross-sectional study.BMC gastroenterology · 2025Article
- Prevalence of metabolic dysfunction-associated fatty liver disease among health check-up attendees: A retrospective study conducted in Vietnam.World journal of gastroenterology · 2025Article
- A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction-associated fatty liver disease in newly diagnosed type 2 diabetes patients.Journal of diabetes investigation · 2025Article
- Potential alternative and novel biomarkers for paediatric MAFLD: exploratory evidence from a Chinese cohort.BMC gastroenterology · 2025Article
- Application of machine learning on health examination data for predicting the decrease of bone mineral density.International journal of clinical and experimental pathology · 2025Article
- Comparative effects of different loads of aerobic exercise on lipid metabolism in MASLD rats: a perspective from the gut-liver axis.Frontiers in medicine · 2025Article
- The Global Epidemic of Metabolic Fatty Liver Disease.Current cardiology reports · 2024Review
- Prevalence and Characteristics of Metabolic Dysfunction-Associated Fatty Liver Disease among an Iranian Adult Population with Ethnic and Genetic Diversity: Results of the PolyIran-Liver Study.Middle East journal of digestive diseases · 2024Article
- Metabolic-associated fatty liver disease and sarcopenia: A double whammy.World journal of hepatology · 2024Review
- Protocol for a Longitudinal Cohort Study to Understand Characteristics and Risk Factors Underlying Vibration-Controlled Transient Elastography-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease Children.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Association Between Serum Uric Acid Levels and Metabolic-Associated Fatty Liver Disease in Southeast China: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- [Establishment and Analysis of Risk Prediction Model for Metabolic Dysfunction-Associated Fatty Liver Disease in Physical Examination Population].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023Article
- Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease.Metabolites · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the incidence and characteristics of metabolic-associated fatty liver disease (MAFLD) in individuals undergoing physical examination in Liaoning Province (China).
designRetrospective study.
settingSingle centre.
participantsAdults who underwent routine health examination at Xikang Medical Center in Liaoning Province (Shenyang, Dandong and Dalian cities) between January 2014 and December 2018.
resultsAmong the 204 394 included subjects, 71 756 were diagnosed with MAFLD, accounting for 35.28%. The total prevalence of MAFLD in Shenyang, Dandong and Dalian cities over the past 5 years was 35.8%, 40.41% and 31.7%, respectively. Men had a prevalence of 46.12%, which was higher than in women (21.80%). The percentage of MAFLD in body mass index (BMI) <23 kg/m
conclusionThe prevalence of MAFLD in Liaoning Province was found to be associated with sex, cities with different economic statuses, BMI and multiple metabolic indicators.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.